Fibroblast growth factor receptors (FGFRs) play diverse roles in control of cell proliferation, cell differentiation, angiogenesis, and development. Activating mutations of FGFRs in the germline have long been known to cause a variety of skeletal developmental disorders, but it is only recently that a similar spectrum of somatic FGFR mutations has been associated with human cancers. Many of these somatic mutations are gain-of-function and oncogenic and create dependencies in tumor cell lines harboring such mutations. A combination of knock-down studies and pharmaceutical inhibition in preclinical models has further substantiated genomically-altered FGFR as a therapeutic target in cancer, and the oncology community is responding with clinical trials evaluating multi-kinase inhibitors with anti-FGFR activity and a new generation of specific pan-FGFR inhibitors.
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Physiological FGFR activation
Members of the fibroblast growth factor receptor (FGFR) receptor tyrosine kinase (RTK) family, FGFR1-4, are differentially activated by binding to a subset of 18 fibroblast growth factors (FGFs) in conjunction with heparan sulfate proteoglycan, which stabilizes and sequesters FGFs [1] . Ligand specificity of FGFR1-3 is, in part, controlled by an alternative splicing event that affects the third immunoglobulin (Ig) loop (IgIII) in the ligand-binding domain, resulting in a "IIIb" isoform preferentially expressed in epithelial cells and a "IIIc" isoform preferentially expressed in mesenchymal cells . FGF3, FGF7, FGF10, and FGF22 exclusively bind the IIIb isoform; FGF1 binds both the IIIb and IIIc isoforms; and the remaining 13 FGF family ligands for which FGFR-stimulatory activity has been demonstrated preferentially bind the IIIc isoform [2] . Importantly, ligand expression is controlled in a cell-specific manner such that physiological receptor stimulation tends to occur in a paracrine rather than autocrine manner; indeed, a switch to autocrine regulation can promote tumorigenesis [3] .
Binding of cognate ligands induces FGFR dimerization, trans-autophosphorylation, and kinase activation [4] . Downstream signaling events are summarized in Box 1. Most of the original work dissecting the biochemistry of FGFR signal transduction involved primarily FGFR1; surprisingly little is known of the similarities and differences between the four family members. However, activating somatic mutations in all four FGFR genes have now been found in diverse human cancers, indicating the potential of FGFR inhibition as a powerful new approach to targeted cancer therapy.
FGFR3 mutations in cancer
FGFR3 was the first FGFR family member reported to be somatically mutated in cancer, specifically in multiple myeloma [5] (Table 1) . Recurring translocations between the immunoglobulin heavy chain (IGH) locus and FGFR3 were identified in 25% of patient samples and cell lines tested, frequently resulting in elevated expression levels of FGFR3 [5, 6] .
Translocation only roughly correlates with increased FGFR3 protein expression [5, 7] , and there is currently insufficient functional data to conclude that translocation-driven increases in wildtype protein expression are sufficient for tumorigenesis, perhaps implicating the consistentlyoverexpressed reciprocal translocation partner, multiple myeloma SET domain protein (MMSET) in these cases instead [8] . However, sequence analysis showed that about 10% of FGFR3 translocations harbor recurring somatic mutations of FGFR3, including alleles encoding Y373C, K650E, and K650M, correlating more accurately with increased FGFR3 expression [5] .
Interestingly, these alleles and the subsequently-identified allele encoding R248C [9] have been reported in three sporadic skeletal dysplasias that result from germline mutation of FGFR3:
R248C and Y373C in thanatophoric dysplasia type I, K650E in thanatophoric dysplasia type II, and K650M in severe achondroplasia with developmental delay and acanthosis (SADDAN) syndrome [10] [11] [12] , thus establishing a paradigm that would repeatedly apply to FGFR family mutation in cancer.
Studied in the context of thanatophoric dysplasia and SADDAN syndrome, ectopicallyexpressed Y373C, K650E, and K650M FGFR3 displayed constitutively elevated kinase activity [11, 13, 14] . The K650E substitution is located in the activation loop of the FGFR3 kinase domain and presumably directly affects the active site conformation of the mutant protein [15] . In contrast, the Y373C and R248C substitutions located in the extracellular region of FGFR3 introduce an unpaired cysteine which results in the formation of intermolecular disulfide bonds, leading to constitutive receptor dimerization and therefore constitutive kinase activation [13] . The activated alleles were also tested in cell-based transformation assays. Whereas expression of the wild-type FGFR3 had no effect on colony formation in soft agar, both the Y373C and K650E-encoding alleles supported anchorage-independent growth of NIH-3T3 cells, indicating that these alleles are in fact oncogenic [16] . Ectopic expression of FGFR3 K650E in Ba/F3 cells additionally conferred interleukin-3 (IL-3)-independent proliferation, a phenotype often associated with expression of oncogenic RTKs.
Recurring activating mutations of FGFR3 were subsequently detected in additional tumor types (Table 1) , including 35% of urothelial cell (bladder) carcinomas and 25% of cervical carcinomas, as well as 39% of benign seborrheic keratoses [17, 18] . In addition to the mutations described above, the S249C and G370C substitutions that introduce an unpaired cysteine, resulting in constitutive dimer formation, were found in bladder carcinomas as well as thanatophoric dysplasia type I patients [10, 13, 17, 19, 20] . In contrast to transformed phenotypes observed in NIH-3T3 cell assays, neither FGFR3 S249C nor Y373C supported anchorage-independent growth of immortalized normal human urothelial cells, which are assumed to be more physiologically relevant to bladder cancer than NIH-3T3 cells, with the caveat that no positive control data was presented for this assay [21] . These two mutants did, however, confer increased cell saturation density [21] .
FGFR3 mutations in urothelial cell carcinomas correlate with lower tumor grade.
However, within the stratum of low-grade non-muscle invasive tumors, FGFR3 mutation correlates with higher risk of recurrence compared to tumors without FGFR3 mutation [22, 23] .
Therefore, although FGFR3 mutations are found primarily in low-grade tumors, treatment targeted to FGFR3 mutations might still benefit a subset of bladder cancer patients.
Seborrheic keratosis is a common benign skin tumor originating from keratinocytes of the epidermis, the prevalence of which increases with age [18] . A spectrum of somatic alleles similar to that found in multiple myeloma and urothelial cell carcinoma are also found in seborrheic keratosis (Table 1) , with the addition of S371C, another substitution observed in patients with thanatophoric dysplasia type I that results in receptor dimerization [12, 13, 18] .
More recently, the FGFR3 K650E substitution was identified in spermatocytic seminomas, rare testicular malignancies that occur in aging patients. An observed clonal expansion of activated K650 mutants in sperm (but not blood) that correlated with increased donor age indicates that positive selection of sperm harboring activated FGFR3 K650E mutants underlies both the sporadic incidence of spermatocytic seminoma and the germline transmission of thanatophoric dysplasia type II [24] .
Recurring oncogenic mutations of FGFR3 have thus been identified in several tumor types. It is reasonable to expect that additional somatic alleles of FGFR3 previously associated with similar germline skeletal dysplasia syndromes will be oncogenic as well. However, for novel FGFR3 mutations, detailed functional studies will be required to distinguish "driver" mutations that contribute to tumorigenesis from "passenger" mutations that provide no fitness benefit for the tumor.
FGFR2 mutations in cancer
The next most significant discovery of FGFR family mutation in cancer was the identification of FGFR2 mutations in endometrial carcinoma [25, 26] (Table 1) and K650E (Figure 2 ). Substitution of these two residues activates kinase activity by disengaging a "molecular brake" that maintains FGFR2 in an inactive conformation through a network of hydrogen bonds that inhibits movement of the N lobe toward the C lobe and is required for alignment of catalytic residues [15] .
A subset of FGFR2 mutations found in endometrial carcinoma have been tested for oncogenic potential in cell-based transformation assays, and most have scored positive (Table 1) , further suggesting a causative role in cancer for many of these alleles [25, 28] . The S252W and P253R substitutions, in particular, activate FGFR2 in a manner that is unique in oncology to the FGFR family. These altered residues lie in the ligand binding region and confer a gain in ligand binding promiscuity, such that ligands expressed by the epithelial cells that normally only bind the mesenchymally expressed "c" isoform of FGFR2 can now bind the S252W "b" isoform and establish an autocrine loop [29] .
FGFR2 somatic mutations have also been identified in other cancers, but it is difficult to impute causation in the absence of functional data. Nevertheless, based on our experience to date, it is reasonable to expect that somatic alleles found in cancer would contribute to tumor formation if they are also observed in the germline of craniosynostosis patients. 
FGFR4 mutations in cancer
FGFR4 is perhaps the least well-studied of the FGFR family members, and it is only recently that its contributions to cancer have begun to be uncovered. Recurring somatic kinase domain mutations of FGFR4 have recently been described in 8% of rhabdomyosarcoma patients Although not found as a somatic mutation, a SNP in FGFR4 is associated with increased disease aggressiveness. The Gly 388 -encoding allele (G388) of FGFR4 has been associated with a shorter time to progression after initial surgery and adjuvant therapy in breast cancer patients, and also correlated with lymph node metastasis and disease recurrence in prostate cancer patients These data suggest that FGFR4 also plays a role in tumorigenesis for several tumor types.
It should be noted that FGFR4 was found to be significantly mutated in lung adenocarcinoma 
Validation of FGFRs as therapeutic targets

Agents with anti-FGFR activity in clinical trials
Several small molecules with activity against FGFRs are currently in preclinical or clinical development. The majority of these are multi-kinase inhibitors often designed primarily as anti-angiogenic inhibitors with activity against vascular endothelial growth factor receptors (VEGFRs) and platelet-derived growth factor receptors (PDGFRs) and, as such, often don't demonstrate sufficiently potent anti-FGFR activity. However, at least two second-generation pan-FGFR inhibitors that have increased specificity for the FGFR family have entered Phase I trials and several more are in preclinical development, further supporting the emerging role of FGFRs as therapeutic targets in oncology (Table 2) . .
TKI-258 (Novartis) is the multi-target kinase inhibitor with the best evidence for
physiologically-relevant efficacy against activated FGFRs. TKI-258 is an orally administered, multi-targeted growth factor receptor inhibitor that has activity against FGFRs, VEGFRs, PDGFR, KIT, and FLT3 [77] . In a move that reflects current clinical trial design with new targeted agents, TKI258 is being evaluated in bladder cancer patients, with the inclusion criterion of availability of archival tumor tissue for FGFR3 mutation testing to enable correlative studies (NCT00790426). Additionally, it is being evaluated in advanced breast cancer patients with and without FGFR1 amplification (NCT00958971), and relapsed multiple myeloma cases with and without the t(4;14) translocation often associated with FGFR3 amplification (NCT01058434). Of note, a more specific pan-FGFR inhibitor, BGJ398 (Novartis), is currently being evaluated in a phase I study in advanced solid malignancies restricted to patients with advanced solid tumors demonstrating either FGFR1 or FGFR2 amplification or FGFR3 mutation for whom no further effective treatment exists (NCT01004224).
Brivanib (Bristol Myers Squibb) is a dual tyrosine kinase inhibitor of VEGFR and FGFR
signaling which has shown activity against metastatic solid tumors refractory to standard therapy in Phase I clinical trials and is currently being evaluated in a large number of trials primarily as an anti-angiogenic agent [78] . Based on its additional anti-FGFR activity, it is also being tested in endometrial cancer (NCT00888173); however, in contrast to TKI258, no data has been published regarding whether brivanib shows in vitro or in vivo tumor growth inhibition in cell line models driven by mutated or amplified FGFRs.
E7080 (Eisai) has activity against VEGFRs, FGFRs, PDGFRs and KIT [79] and is currently in phase II clinical trials for a wide range of solid malignancies. Based on a partial response in the Phase I trial, a Phase II trial was opened to examine the efficacy of E7080 in patients with metastatic endometrial cancer (NCT01111461). Several additional molecules being developed as anti-angiogenic compounds are being trialed in endometrial cancer (AZ2171, NCT01132820; BIBF1120, NCT01225887). Should there be any partial or complete responses in these trials it will be interesting to correlate these with the mutation status of FGFR2. 
Concluding remarks
The field of anti-FGFR therapy is in its infancy; therefore it is too soon to predict whether 
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